Two different types of obesity treatment drugs are currently available in the market, including orlistat, which reduces intestinal fat absorption through inhibition of pancreatic lipase, and sibutramine, which is an anorectic. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.